Comparison of individual patient data from real-world experience with the ADAURA study for resected stage IB-IIIA EGFR-mutated non-small cell lung cancer

被引：0
|
作者：
Jung, Hyun Ae
Lee, Junho
Park, Boram
Park, Sehhoon
Sun, Jong-Mu
Lee, Se-Hoon
Ahn, Jin Seok
Ahn, Myung-Ju
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-3830
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3830
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA
    Tsuboi, M.
    Wu, Y-L.
    Grohe, C.
    John, T.
    Majem Tarruella, M.
    Wang, J.
    Kato, T.
    Goldman, J. W.
    Kim, S-W.
    Yu, C-J.
    Vu, H. Vinh
    Mukhametshina, G.
    Akewanlop, C.
    de Marinis, F.
    Shepherd, F. A.
    Urban, D.
    Stachowiak, M.
    Bolanos, A. L.
    Huang, X.
    Herbst, R. S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1413 - S1414
  • [2] Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC).
    Herbst, Roy S.
    Tsuboi, Masahiro
    John, Tom
    Kato, Terufumi
    Majem, Margarita
    Grohe, Christian
    Wang, Jie
    Goldman, Jonathan W.
    Lu, Shun
    Su, Wu-Chou
    De Marinis, Filippo
    Shepherd, Frances A.
    Lee, Ki Hyeong
    Le, Nhieu
    Dechaphunkul, Arunee
    Kowalski, Dariusz M.
    Poole, Lynne
    Stachowiak, Marta
    Rukazenkov, Yuri
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17)
  • [3] Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA
    Wu, Y-L.
    Tsuboi, M.
    Grohe, C.
    John, T.
    Tarruella, M. Majem
    Wang, J.
    Kato, T.
    Goldman, J. W.
    Kim, S-W.
    Yu, C-J.
    Vu, H. Vinh
    Mukhametshina, G.
    Akewanlop, C.
    de Marinis, F.
    Shepherd, F. A.
    Urban, D.
    Stachowiak, M.
    Bolanos, A.
    Huang, X.
    Herbst, R. S.
    ANNALS OF ONCOLOGY, 2022, 33 : S1548 - S1549
  • [4] Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC).
    Herbst, Roy S.
    Tsuboi, Masahiro
    John, Tom
    Kato, Terufumi
    Majem, Margarita
    Grohe, Christian
    Wang, Jie
    Goldman, Jonathan W.
    Lu, Shun
    Su, Wu-Chou
    de Marinis, Filippo
    Shepherd, Frances A.
    Lee, Ki Hyeong
    Le, Nhieu
    Dechaphunkul, Arunee
    Kowalski, Dariusz M.
    Poole, Lynne
    Stachowiak, Marta
    Rukazenkov, Yuri
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17_SUPPL)
  • [5] Long-term tolerability of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC) from ADAURA
    John, T.
    Grohe, C.
    Goldman, J.
    De Marinis, F.
    Kato, T.
    Wang, Q.
    Choi, J-H.
    Melotti, B.
    Fidler, M.
    Sainsbury, L.
    Stachowiak, M.
    Taggart, S.
    Wu, Y-L.
    Tsuboi, M.
    Herbst, R. S.
    Tarruella, M. Majem
    ANNALS OF ONCOLOGY, 2022, 33 : S1548 - S1548
  • [6] Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial
    Herbst, Roy S.
    Wu, Yi-Long
    John, Thomas
    Grohe, Christian
    Majem, Margarita
    Wang, Jie
    Kato, Terufumi
    Goldman, Jonathan W.
    Laktionov, Konstantin
    Kim, Sang-We
    Yu, Chong-Jen
    Vu, Huu Vinh
    Lu, Shun
    Lee, Kye Young
    Mukhametshina, Guzel
    Akewanlop, Charuwan
    de Marinis, Filippo
    Bonanno, Laura
    Domine, Manuel
    Shepherd, Frances A.
    Urban, Damien
    Huang, Xiangning
    Bolanos, Ana
    Stachowiak, Marta
    Tsuboi, Masahiro
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (10) : 1830 - +
  • [7] Molecular residual disease (MRD) analysis from the ADAURA trial of adjuvant (adj) osimertinib in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC)
    John, Tom
    Grohe, Christian
    Goldman, Jonathan W.
    Kato, Terufumi
    Laktionov, Konstantin K.
    Bonanno, Laura
    Tiseo, Marcello
    Majem, Margarita
    Domine, Manuel, Sr.
    Ahn, Myung-Ju
    Perol, Maurice
    Hartmaier, Ryan
    Robichaux, Jacqulyne
    Bhetariya, Preetida
    Markovets, Aleksandra
    Rukazenkov, Yuri
    Muldoon, Caitlin
    Herbst, Roy S.
    Tsuboi, Masahiro
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer
    Herbst, Roy S.
    John, Thomas
    Grohe, Christian
    Goldman, Jonathan W.
    Kato, Terufumi
    Laktionov, Konstantin
    Bonanno, Laura
    Tiseo, Marcello
    Majem, Margarita
    Domine, Manuel
    Ahn, Myung-Ju
    Kowalski, Dariusz M.
    Perol, Maurice
    Sriuranpong, Virote
    Ozguroglu, Mustafa
    Bhetariya, Preetida
    Markovets, Aleksandra
    Rukazenkov, Yuri
    Muldoon, Caitlin
    Robichaux, Jacqulyne
    Hartmaier, Ryan
    Tsuboi, Masahiro
    Wu, Yi-Long
    NATURE MEDICINE, 2025,
  • [9] Real-world outcomes in resected stage IB-IIIA EGFR mutated NSCLC in Canada: Analysis from the POTENT study
    Kuruvilla, M. S.
    Syed, I.
    Gwadry-Sridhar, F.
    Sachdeva, R.
    Pencz, A.
    Zhan, L.
    Hueniken, K.
    Patel, D.
    Balaratnam, K.
    Khan, K.
    Grant, B.
    Sheffield, B.
    Noy, S.
    Singh, K. P.
    Liu, L.
    Ralibuz-Zaman, M.
    Davis, B.
    Moldaver, D.
    Shanahan, M.
    Cheema, P.
    ANNALS OF ONCOLOGY, 2021, 32 : S931 - S932
  • [10] Adjuvant Osimertinib in Resected EGFR-Mutated Stage IBeIIIA Non-Small Cell Lung Cancer: Updated ADAURA Results
    Herbst, R. S.
    Wu, Y. -L.
    Grohe, C.
    John, T.
    Majem, M.
    Wang, J.
    Kato, T.
    Goldman, J. W.
    Kim, S. -W.
    Yu, C. -J.
    Vu, H. V.
    Mukhametshina, G.
    Akewanlop, C.
    de Marinis, F.
    Shepherd, F. A.
    Urban, D.
    Stachowiak, M.
    Bolanos, A.
    Huang, X.
    Tsuboi, M.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E4 - E4
12345